phrykt

RxSight, Inc. (RXST): who owns it and who trades it

As of Nov 16, 2026, RXST insiders reported 3 open-market sales worth $104K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Mark Wilterding (CFO), with $54K. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling RxSight

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns RXST

150 funds and institutions reported RXST shares worth $201M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 14.0%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

BlackRock, Inc.14.0%
Millennium Management LLC7.3%
No Street GP LP5.0%
Nomura Holdings Inc4.8%
D. E. Shaw & Co., Inc.4.8%
Vanguard Capital Management LLC4.0%
AQR Capital Management LLC3.7%
Acadian Asset Management LLC3.6%
Federated Hermes, Inc.2.9%
Two Sigma Investments, LP2.8%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.5.79M13.99%$27.9M+82%
Millennium Management LLC3.03M7.32%$14.6M+47%
No Street GP LP2.06M4.96%$9.9M+3%
Nomura Holdings Inc2.00M4.83%$9.6MNo change
D. E. Shaw & Co., Inc.1.99M4.80%$9.6M+1%
Vanguard Capital Management LLC1.68M4.05%$8.1M-1%
AQR Capital Management LLC1.53M3.71%$7.4M+141%
Acadian Asset Management LLC1.50M3.63%$7.2M+47%
Federated Hermes, Inc.1.20M2.90%$5.8M+11%
Two Sigma Investments, LP1.15M2.77%$5.5M-12%
Healthcare of Ontario Pension Plan Trust Fund1.13M2.73%$5.5MNo change
UBS Group AG1.02M2.45%$4.9M+324%
Jacobs Levy Equity Management, Inc998,5692.41%$4.8M-6%
Marshall Wace, LLP995,9162.41%$4.8M–
Geode Capital Management, LLC984,9782.38%$4.7M+7%
State Street Corp851,5122.06%$4.1M+6%
Point72 Asset Management, L.P.778,2521.88%$3.8M+6%
Grandeur Peak Global Advisors, LLC722,4401.75%$3.5M+55%
Schonfeld Strategic Advisors LLC701,4171.69%$3.4M+266%
Citadel Advisors LLC700,7361.69%$3.4M-37%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, RXST insiders reported $0 of open-market purchases and $104K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$104K
3 trades, 3 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Sep 2, 2026
Filed Sep 2, 2026

Purchases and sales by month

$104K$104KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 2, 2026Ronald M MD KurtzChief Medical OfficerSale5,100$6.96$35.5KForm 4
Sep 2, 2026Mark WilterdingCFOSale7,765$6.96$54KForm 4
Sep 2, 2026Ilya GoldshlegerChief Operating OfficerSale2,041$6.96$14.2KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Mark WilterdingChief Financial Officer–$54KSep 2, 2026
Ronald M MD KurtzChief Medical Officer–$35.5KSep 2, 2026
Ilya GoldshlegerChief Operating Officer–$14.2KSep 2, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

RXST short interest

Moderate short interest. 8.7% of RXST shares are sold short: about 1 share in 12. Over the last 12 reports the number of shares short went down 25%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 3.63M RXST shares were sold short, 8.7% of the shares outstanding, down 11.8% from the report before. At the average daily volume of 598,318 shares, buying them all back would take about 6.1 trading days (days to cover).

Shares short, % of all shares

8.67%May 15Oct 3014.0%

Days to cover

6.1May 15Oct 306.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20263.63M8.67%-12%598,3186.1
Oct 15, 20264.12M9.90%+1%674,6956.1
Sep 30, 20264.09M9.83%+3%882,8474.6
Sep 15, 20263.98M9.56%+3%720,4355.5
Aug 31, 20263.88M9.32%-9%837,8794.6
Aug 14, 20264.26M10.24%+5%942,4554.5
Jul 31, 20264.06M9.75%+6%1.01M4.0
Jul 15, 20263.84M9.28%-30%1.38M2.8
Jun 30, 20265.51M13.32%+32%1.60M3.4
Jun 15, 20264.18M10.10%+0%1.08M3.9
May 29, 20264.17M10.08%-14%695,2836.0
May 15, 20264.85M11.72%-13%804,9506.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

RxSight company events

RxSight filed 13 reports on Form 8-K in the last 12 months, 6 of them about an important change (leadership). The latest was on Nov 3, 2026.

  1. Nov 3, 2026ResultsReleased financial results. Filing
  2. Aug 5, 2026ResultsReleased financial results. Filing
  3. Jul 15, 2026LeadershipThe Board of Directors of RxSight, Inc. appointed Aziz Mottiwala to serve as the Company’s President and Chief Executive Officer, effective as of Mr. Mottiwala’s first day of employment with the Company, which is expected to be July 20, 2026, replacing Ron Kurtz, M.D. in such roles. Filing
  4. Jul 6, 2026AgreementWe entered into a License, Collaboration and Development Agreement with Alcon Pharmaceuticals, Ltd, pursuant to which we will collaborate with Alcon to develop and commercialize light-adjustable versions of certain Alcon simultaneous vision intraocular lenses by incorporating RxSight Light… Filing
  5. Jul 6, 2026ResultsReleased financial results. Filing
  6. Jun 16, 2026VoteReported shareholder vote results. Filing
  7. May 6, 2026ResultsReleased financial results. Filing
  8. Mar 19, 2026LeadershipAmended an earlier report. RxSight, Inc. filed a Current Report on Form 8-K with the Securities and Exchange Commission to report, among other things, the appointment of Mark Wilterding as the Company’s Chief Financial Officer. Filing
  9. Feb 25, 2026ResultsReleased financial results. Filing
  10. Jan 12, 2026LeadershipThe Company appointed Mark Wilterding as its Chief Financial Officer (and principal financial and accounting officer), effective January 11, 2026, replacing Shelley Thunen in such capacities. Filing
  11. Dec 23, 2025LeadershipIn connection with the previously announced pending transition of Shelley Thunen from her position as the Company’s Chief Financial Officer (and principal financial and accounting officer), on December 23, 2025, RxSight, Inc. and Ms. Thunen entered into a transition agreement and release of claims… Filing
  12. Dec 22, 2025LeadershipShelley Thunen notified RxSight, Inc. of her intention to transition from her position as the Company’s Chief Financial Officer (and principal financial and accounting officer), effective upon the sooner of the appointment of her successor as Chief Financial Officer or January 31, 2026. Filing
  13. Dec 19, 2025LeadershipThe Board of Directors of RxSight, Inc. appointed Eric Weinberg to the executive officer position of Chief Business Development Officer concurrent with his transition from the Chief Commercial Officer position on the same date. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

RxSight financials

Famous investors that hold RXST

5 of the 50 well-known investors we track reported holding RXST in their latest 13F filing. The largest position is Israel Englander's, worth $10.5M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20262.14M$10.5M0.0%-29%
Steve Cohen · Point72 Asset ManagementQ3 20261.43M$7M0.0%+84%
Paul Tudor Jones · Tudor Investment CorpQ3 2026353,962$1.7M0.0%+169%
Ken Griffin · Citadel AdvisorsQ3 2026258,665$1.3M0.0%-63%
Jim Simons · Renaissance TechnologiesQ3 2026226,993$1.1M0.0%+61%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 10 filings named RXST in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Point72 Asset Management, L.P.13G/A3.4%
Nov 16, 2026Point72 Asset Management, L.P.13G/A3.4%
Nov 10, 2026Millennium Management LLC13G5.2%
Nov 10, 2026Millennium Management LLC13G5.2%
Nov 2, 2026Millennium Management LLC13G/A5.1%
Nov 2, 2026Millennium Management LLC13G/A5.1%
Oct 27, 2026BlackRock Portfolio Management LLC13G/A8.4%
Oct 27, 2026BlackRock, Inc.13G/A6.9%
Oct 27, 2026BlackRock, Inc.13G/A6.9%
Oct 27, 2026BlackRock Portfolio Management LLC13G/A8.4%

Questions about RxSight, Inc. (RXST) stock

Who owns the most RXST stock?

The largest reported owner of RxSight, Inc. (RXST) is BlackRock, Inc., with 14.0% of the company. In total, 150 funds and institutions reported holding RXST at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are RXST insiders buying or selling?

In the last 12 months, RXST insiders reported no open-market purchases and 3 sales worth $104K. The latest trade was on Sep 2, 2026. See every trade.

What is the short interest in RXST?

As of Oct 30, 2026, 3.63M RXST shares were sold short, 8.7% of the shares outstanding, down 11.8% from the report before. At the average daily volume of 598,318 shares, buying them all back would take about 6.1 trading days (days to cover). See the history.

Which famous investors hold RXST?

5 of the 50 well-known investors we track reported RXST in their latest 13F filing, including Israel Englander, Steve Cohen, Paul Tudor Jones. The largest position is worth $10.5M. See all holders.

Executive pay

RxSight's chief executive was paid a total of $4.7M for the year ended Dec 31, 2025, down 33% from $7M the year before. In the last 12 months, RxSight's executives and directors bought no stock on the open market and sold $104K.

Chief executive, total pay$4.7MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Other top executives, average$2.5MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.